343 related articles for article (PubMed ID: 37356995)
1. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
2. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
3. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
4. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
5. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
6. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract][Full Text] [Related]
7. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Andriani A; Elli E; Trapè G; Villivà N; Fianchi L; Di Veroli A; Niscola P; Centra A; Anaclerico B; Montanaro G; Martini V; Aroldi A; Carmosino I; Voso MT; Breccia M; Montanaro M; Foà R; Latagliata R
Hematol Oncol; 2019 Aug; 37(3):291-295. PubMed ID: 31050810
[TBL] [Abstract][Full Text] [Related]
9. The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in
Pan Y; Wang X; Wen S; Liu X; Yang L; Luo J
Hematology; 2022 Dec; 27(1):902-908. PubMed ID: 36000955
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.
Chen D; Geyer J; Bagg A; Hasserjian R; Weinberg OK
Int J Lab Hematol; 2024 Apr; ():. PubMed ID: 38665121
[TBL] [Abstract][Full Text] [Related]
11. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Badar T; Kantarjian HM; Ravandi F; Jabbour E; Borthakur G; Cortes JE; Pemmaraju N; Pierce SR; Newberry KJ; Daver N; Verstovsek S
Leuk Res; 2015 Sep; 39(9):950-6. PubMed ID: 26183878
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090
[No Abstract] [Full Text] [Related]
14. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Tefferi A; Lasho TL; Abdel-Wahab O; Guglielmelli P; Patel J; Caramazza D; Pieri L; Finke CM; Kilpivaara O; Wadleigh M; Mai M; McClure RF; Gilliland DG; Levine RL; Pardanani A; Vannucchi AM
Leukemia; 2010 Jul; 24(7):1302-9. PubMed ID: 20508616
[TBL] [Abstract][Full Text] [Related]
15. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
McNamara CJ; Panzarella T; Kennedy JA; Arruda A; Claudio JO; Daher-Reyes G; Ho J; Siddiq N; Devlin R; Tsui H; Su J; Stockley T; Sukhai M; Kanwar N; Chan S; Maze D; Schimmer A; Schuh A; Sibai H; Viswabandya A; Yee K; Minden MD; Kamel-Reid S; Gupta V
Blood Adv; 2018 Oct; 2(20):2658-2671. PubMed ID: 30327374
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
17. A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.
Chen D; Fuda F; Weinberg O
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():78-81. PubMed ID: 34288445
[TBL] [Abstract][Full Text] [Related]
18. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
Lyu XD; Li YW; Guo Z; Xin YP; Hu JY; Fan RH; Song YP
Zhonghua Nei Ke Za Zhi; 2020 Jan; 59(1):35-39. PubMed ID: 31887834
[No Abstract] [Full Text] [Related]
19. The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.
Şahin E; Yönal-Hindilerden İ; Hindilerden F; Aday A; Nalçacı M
Turk J Med Sci; 2022 Feb; 52(1):150-165. PubMed ID: 34482679
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of
Yönal-Hindilerden İ; Şahin E; Hindilerden F; Dağlar-Aday A; Nalçacı M
Turk J Haematol; 2023 Aug; 40(3):174-182. PubMed ID: 37584526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
